Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

lating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through June 30, 2011, it incurred net losses and negative cash flows from operating activities of approximately $63.0 million and $48.9 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2011, the Company had cash and cash equivalents of approximately $3.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan o
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    2. Bion Announces New U.S. Patent for Phosphorus Removal
    3. ViaCyte Announces Executive Management Changes
    4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
    5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
    6. Osteologix Announces Completion of Corporate Consolidation
    7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
    8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
    9. Rigel Announces Second Quarter 2011 Financial Results
    10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
    11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
    (Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
    (Date:7/10/2014)... 2014 Terascala, the industry leader in ... Swahn, a former vice president of product management for ... president of marketing. Terascala’s software when combined with leading ... the highest performance and most reliable solutions for processing ... Terascala’s channel expansion and broaden its product portfolio. His ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
    Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
    ... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, today,announced that Ron ... Russell, Vice President, Finance, will be attending the,Goldman ... in New,York City in order to meet with ...
    ... Nektar,Therapeutics, (Nasdaq: NKTR ) President and Chief Executive ... upcoming UBS 2008 Global Life,Sciences Conference in New York ... 23, 2008 at 10:30 a.m. ET., The presentation ... posted,on the Investor Relations, Events Calendar section of the ...
    ... Finger Nuclease Platform enables Precise, Permanent, and ... Heritable Modification of the Genome, ... CompoZr(TM) platform of zinc finger nuclease (ZFN),reagents. The CompoZr ZFN ... to target and precisely manipulate the genome,of living cells, resulting ...
    Cached Biology Technology:Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 2Sigma-Aldrich Launches Breakthrough Genome-Editing Tools 3
    (Date:7/11/2014)... set a "mouse TRAP" to capture the early signs ... published in the Journal of Clinical Investigation . ... TRAP to extract cellular and genetic information from a ... the Rockefeller Institute for Medical Research in 2008, TRAP ... or ribosomes, of the cell type of interest. Scientists ...
    (Date:7/11/2014)... Shenzhen, China Researchers from Salk Institute for Biological ... time evaluated the safety and reliability of the ... a new method, TALEN-HDAdV, which could significantly increased ... (hiPSC). This study published online in Cell ... for stem cell-based gene therapy. , The combination ...
    (Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
    Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
    ... beauty products. According to the beauty industry liposomes ... skin and release the active ingredients so that they ... the skin. Research from University of Southern ... transporting themselves deep into the skin, and thus they ...
    ... Amsterdam, NL, 19 February 2013 Raman spectroscopy ... and is a powerful tool for tissue classification ... challenges to using the method in a clinical ... wavelength-modulated Raman spectroscopy, opening the door to wider ...
    ... A new species of scorpion, Vaejovis brysoni, was found in ... scorpion of the same group also inhabits this mountain range, ... group species distributed on the same mountain. The study ... Zookeys . These mountains overlook the city of ...
    Cached Biology News:Don't trust liposomes in your beauty products 2Breakthrough study opens door to broader biomedical applications for Raman spectroscopy 2
    AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
    Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
    Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
    Biology Products: